Designs on Diabetes Drugs

Abstract

In this chapter, we examine how the neo-liberal deregulatory agenda has accentuated the mis-direction of innovative pharmaceutical testing and evaluation. In particular, we show how the neo-liberal hegemony within drug regulatory policy of defining efficiency of regulatory agencies almost entirely in term of the acceleration of review and marketing approval times has inhibited and neglected the need to improve the nature and design of drug testing and evaluation in the interests of health. This chapter is concerned with innovative pharmaceuticals to treat diabetes, which came to the market in both the EU and the US via the regular approval routes.